Kelsey R. Monson

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors

David M. Hyman, Alexandra Snyder, Richard D. Carvajal et al. · Cancer Chemotherapy and Pharmacology · 2015 · 21 citations

Medicine, Oncology, Pharmacology +13

Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort

Kelsey R. Monson, Mandy Goldberg, Hui‐Chen Wu et al. · Breast Cancer Research · 2020 · 16 citations · Full text

Public Health, Oncology, Cancer Epidemiology +6

Altered salivary microbiota associated with high-sugar beverage consumption

Xiaozhou Fan, Kelsey R. Monson, Brandilyn A. Peters et al. · Scientific Reports · 2024 · 16 citations · Full text

Dentistry, Microbiology, Oral Biology +17

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

Lillian M. Smyth, Kelsey R. Monson, Komal Jhaveri et al. · Investigational New Drugs · 2017 · 14 citations · Full text

Medicine, Oncology, Pharmacology +16

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

Kelsey R. Monson, Robert Ferguson, Joanna E. Handzlik et al. · Nature Medicine · 2025 · 10 citations · Full text

Medicine, Immunology, Oncology +17